Cipla Ltd (CIPL.NS)
|Market Cap (Mil.):||Rs492,110.50|
|Shares Outstanding (Mil.):||802.92|
* Local firms Cipla, Ranbaxy, Cadila among companies affected
MUMBAI - Drugmaker Cipla Ltd has agreed to grant U.S.-based Salix Pharmaceuticals Ltd rights relating to the "Rifaximin complexes" patent family controlled by Cipla, the two companies said on Thursday.
MUMBAI, Sept 18 - Indian drugmaker Cipla Ltd has agreed to grant U.S.-based Salix Pharmaceuticals Ltd rights relating to the "Rifaximin complexes" patent family controlled by Cipla, the two companies said on Thursday.
NEW DELHI/MUMBAI - U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations.
NEW DELHI/MUMBAI, Sept 15 - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
* Cipla named as one of firms dropping out of tender process
* BSE index gains 0.57 pct; NSE ends 0.69 pct higher * Cipla jumps as much as 8.7 pct after key generic launch By Abhishek Vishnoi MUMBAI, Sept 2 - India's benchmark BSE index on Tuesday surged past the psychologically key level of 27,000 to a third consecutive record high as blue-chips such as HDFC Bank gained after recent data raised hopes about the economy. The BSE milestone comes a day after the broader NSE index surpassed the 8,000 level for the first time, provi
Reuters Market Eye - Shares in Cipla Ltd on Tuesday rose as much as 8.7 percent to a record high of 575 rupees after the drugmaker launched an anti-asthma inhaler in Germany and Sweden.
* Cipla Ltd rises as much as 8.7 percent to a record high of 575 rupees. * The drug maker launches an anti-asthma inhaler in Germany and Sweden * The inhaler is a generic version of GlaxoSmithKline Plc's Advair. * Emkay Global upgrades to "buy" from "accumulate" with a target of 671 rupees. * Overall addressable opportunity of generic Advair is $800 million in Europe, Emkay says. (email@example.com / firstname.lastname@example.org)
MUMBAI - India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product.